Prognostic utility of pre‐biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence
Pediatric Allergy and Immunology · 2025-12 · 36 (12)
DOI: 10.1111/pai.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 03.12.2025. Verfasst von Arthur H Owora und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapol…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Products. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, AHRQ HHS, NIH HHS.
Abstract (Originalsprache)
Background
Biologics have been shown to substantially reduce the risk of severe asthma exacerbations (SAEs) among children with moderate or severe asthma; however, not all eligible patients who initiate biologic treatment experience a reduced risk of SAEs.
Methods
Using a longitudinal study design, we analyzed data from 122 children with moderate/severe asthma treated with a biologic by pediatric subspecialists between December 2019 and December 2024. We used logistic and Cox proportional hazards models to identify and quantify the prognostic utility of clinical correlates of increased SAE risk among children with moderate or severe asthma prior to biologic treatment initiation.
Results
Biologic agents (dupilumab, omalizumab, and mepolizumab) had differential effects on the risk of SAE depending on a child's sex ( p = .024), age of treatment initiation ( p = .010), lung function (% FEF 25‐75 predicted: p = .034), and absolute neutrophils ( p = .055). Dupilumab was associated with a higher risk of SAE among female patients. Omalizumab and mepolizumab were associated with a higher risk of SAEs among patients with elevated absolute neutrophils and younger age at treatment initiation. Consideration of these clinical parameters in a multivariable model improved the pre‐treatment prognostic accuracy of SAE risk by 23% compared to reliance on history of SAEs alone (0.86; 95% CI: 0.79, 0.89 vs. 0.63; 95% CI: 0.54, 0.72).
Conclusion
Beyond biologic treatment eligibility, using routinely collected clinical parameters to stratify pre‐treatment SAE risk could improve prognostic accuracy and aid clinicians in tailoring therapy based on a patient's individual risk factors and likelihood of responding to a specific agent to maximize treatment effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
- Translational Informatics, Biostatistics, Epidemiology, and Informatics (TIBE) Lab, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Arthur H Owora
Förderung
- NHLBI NIH HHS
- AHRQ HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Owora, A. H., Jiang, B., Shah, Y., Gaston, B., & Forno, E. (2025). Prognostic utility of pre‐biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence. Pediatric Allergy and Immunology, 36(12). https://doi.org/10.1111/pai.70247
Vancouver
Owora AH, Jiang B, Shah Y, Gaston B, Forno E. Prognostic utility of pre‐biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence. Pediatric Allergy and Immunology. 2025;36(12). doi:10.1111/pai.70247
BibTeX
@article{Owora2025,
author = {Owora, Arthur H and Jiang, Bowen and Shah, Yash and Gaston, Benjamin and Forno, Erick},
title = {Prognostic utility of pre‐biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence},
journal = {Pediatric Allergy and Immunology},
year = {2025},
volume = {36},
number = {12},
doi = {10.1111/pai.70247}
}
EUVIMED